Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view - Najmeddin, Ali; Bahrololoumi Shapourabadi, Mina; Behdani, Mahdi; Dorkoosh, Farid (Biochimica et biophysica acta. General subjects, 2021)
Keywords: Angiotensin-Converting Enzyme 2 - antagonists & inhibitors; Angiotensin-Converting Enzyme 2 - genetics; Angiotensin-Converting Enzyme 2 - immunology; Animals; Antibodies, Neutralizing - biosynthesis; Antibodies, Neutralizing - isolation & purification; Antibodies, Neutralizing - therapeutic use; Antiviral Agents - isolation & purification; Antiviral Agents - metabolism; Antiviral Agents - therapeutic use; Camelus; Covid-19; COVID-19 - immunology; COVID-19 - therapy; COVID-19 - virology; COVID-19 infection; Drug Delivery Systems; drugs; Humans; Immune Sera - chemistry; Immunologic Factors - biosynthesis; Immunologic Factors - isolation & purification; Immunologic Factors - therapeutic use; Lung - drug effects; Lung - immunology; Lung - virology; Molecular Targeted Therapy - methods; mutants; Nanobody; Peptide Library; Protein Binding - drug effects; Pulmonary drug delivery; SARS-CoV-2; SARS-CoV-2 - drug effects; SARS-CoV-2 - genetics; SARS-CoV-2 - immunology; Severe acute respiratory syndrome coronavirus 2; Single-Domain Antibodies - biosynthesis; Single-Domain Antibodies - isolation & purification; Single-Domain Antibodies - therapeutic use; Spike Glycoprotein, Coronavirus - antagonists & inhibitors; Spike Glycoprotein, Coronavirus - genetics; Spike Glycoprotein, Coronavirus - immunology; therapeutics; viruses; Nanobody; SARS-CoV-2; Pulmonary drug delivery; Covid-19